Austin、TXにおける肥満症の臨床試験
Austinとその周辺地域（約30マイル以内）の拠点で、肥満症に関する20件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
被験者募集中第2相
- Elligo Clinical Research Center /ID# 282166, Austin
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
被験者募集中第3相
- Texas Diabetes & Endocrinology, Austin
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
被験者募集中第3相
- Dell Children's Medical Center - PIN, Austin
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
被験者募集中第3相
- IMA Clinical Research Austin, Austin
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
被験者募集中第3相
- FutureSearch Trials of Neurology, Austin
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
被験者募集中第3相
- Austin Heart, Austin
- Velocity Clinical Research - Austin, Austin
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
被験者募集中第2相
- IMA Clinical Research Austin, Austin
Semaglutide for Post-Smoking Cessation Weight Management
被験者募集中第2相健康なボランティア歓迎
- The University of Texas at Austin, Austin
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
被験者募集中第3相
- AURORA-1 Clinical Site, Austin
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
被験者募集中第3相
- AURORA-2 Clinical Site, Austin
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
被験者募集中第3相
- Austin Heart, Austin
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
被験者募集中第3相健康なボランティア歓迎
- ACCOMPLISH-2 Research Site, Austin
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
被験者募集中第2相
- IMA Clinical Research Austin, Austin
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
被験者募集中第3相
- Elligo Clinical Research Center, Austin
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
被験者募集中第3相
- Elligo Clinical Research Center, Austin
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
被験者募集中第3相
- Austin Heart, Austin
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
被験者募集中第3相
- ACCOMPLISH-1 Research Site, Austin
- ACCOMPLISH-1 Research Site, Austin
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
被験者募集中第1相
- Elligo Clin Res Centre, Austin
A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
被験者募集中第1相
- Corxel Investigational Site, Austin
Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity)
被験者募集中健康なボランティア歓迎
- Dell Pediatric Research Center, Austin
- University of Texas at Austin, Austin
他の都市における肥満症の試験
- Houston, TX43件の研究
- Chicago, IL41件の研究
- New York City, NY40件の研究
- San Antonio, TX40件の研究
- Washington, DC33件の研究
- Orlando, FL31件の研究
- Dallas, TX30件の研究
- Boston, MA28件の研究
- Las Vegas, NV27件の研究
- Miami, FL27件の研究
- Baltimore, MD25件の研究
- Jacksonville, FL25件の研究
Austinにおける他の研究
- 非小細胞肺癌30件の研究
- がん（全種類）20件の研究
- 転移性癌19件の研究
- 大腸癌19件の研究
- 心不全18件の研究
- 乳がん18件の研究
- 過体重18件の研究
- 卵巣がん17件の研究
- 子宮内膜がん15件の研究
- 前立腺がん15件の研究
- うつ病14件の研究
- トリプルネガティブ乳がん13件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。